Skip to main content
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE).
Reduced plasmablast frequency is associated with seronegative myasthenia gravis.
Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study.
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.
Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study.
Marked clinical and jitter improvement after eculizumab in refractory myasthenia.
QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
Novel mutation in CNTNAP1 results in congenital hypomyelinating neuropathy.
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.